Vivatides Therapeutics
PrivateLast Round
Series A
Apr 10, 2026
Total Funding Raised
$64M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Vivatides Therapeutics is a biotechnology company developing extrahepatic RNA-targeting therapeutics, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), to treat chronic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivatides Therapeutics Comparables
Compare Vivatides Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Creative Peptides | 79% | |
| BBI Life Sciences Corporation | 78% | |
| Medtide Inc | 76% |
Vivatides Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 10, 2026 | ||||
| Seed | Aug 22, 2025 |
Vivatides Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Highlight Capital | Series A |
| TF Capital | Series A |
| Qiming Venture Partners | Seed, Series A |
| Apricot Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
Raised $54M in Series A funding.
- Aug 22, 2025
$10M raised in Seed round.
Vivatides Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vivatides Therapeutics's valuation, stock price, and market status.
Is Vivatides Therapeutics a public or private company?
Vivatides Therapeutics is a private company.
What is the current stock price of Vivatides Therapeutics?
Vivatides Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Vivatides Therapeutics worth (valuation)?
Valuation information for Vivatides Therapeutics is not publicly available.
Can I buy Vivatides Therapeutics stock?
Vivatides Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vivatides Therapeutics's last funding round?
Vivatides Therapeutics's most recent funding round was Series A on April 10, 2026.
Who are the main investors in Vivatides Therapeutics?
Key investors in Vivatides Therapeutics include Qiming Venture Partners, Apricot Capital.
Will Vivatides Therapeutics IPO soon?
No public IPO plans have been announced for Vivatides Therapeutics.
How can I track Vivatides Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivatides Therapeutics's secondary market activity and sign up for updates.